Syndax Pharmaceuticals
Clinical trials sponsored by Syndax Pharmaceuticals, explained in plain language.
-
New drug combo targets tough leukemia genes in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called SNDX-5613 combined with strong chemotherapy for people newly diagnosed with acute myeloid leukemia (AML) that has specific genetic changes. The main goals are to check safety and find the best dose. About 76 adults with KMT2A, NPM1, …
Phase: PHASE1 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 05:54 UTC
-
New hope for tough leukemias: targeted drug revumenib enters key trials
Disease control Recruiting nowThis study tests a new drug called revumenib in people with certain types of leukemia that have returned or not improved with standard treatments. The trial has two parts: first, finding the safest dose, then testing how well it works in four specific groups of patients. About 44…
Phase: PHASE1, PHASE2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 05:50 UTC
-
New hope for leukemia patients: targeted drug combo shows promise
Disease control Recruiting nowThis study tests whether adding a new drug called revumenib to standard chemotherapy helps people with a specific genetic type of acute myeloid leukemia (AML). About 468 newly diagnosed patients will receive either revumenib plus chemo or a placebo plus chemo. The goal is to see …
Phase: PHASE3 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 13:52 UTC